Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Oncology · Hepatocellular Carcinoma

Understanding Your Outlook: Prognosis and Risk Models

At a Glance

Hepatocellular carcinoma (HCC) prognosis depends on both tumor aggressiveness and your remaining liver function. Doctors use specialized tools like the ALBI grade, Child-Pugh score, and tumor markers such as AFP to accurately estimate your outlook and carefully personalize your treatment plan.

Predicting the outlook for Hepatocellular Carcinoma (HCC) is more complex than with most other cancers. Because HCC typically develops in a liver that is already damaged, your prognosis depends on two separate factors: how aggressive the tumor is and how much liver function you have left [1][2]. Doctors use specialized models and calculators to combine these factors into a risk score.

Assessing Your Liver’s Strength

While the tumor is the target, your liver’s health often determines which treatments you can safely receive.

  • Child-Pugh Score: The traditional system that uses five factors (bilirubin, albumin, clotting time, and signs of fluid or confusion) to grade liver health from A (best) to C (worst) [3].
  • ALBI Grade (Albumin-Bilirubin): A newer, more objective model that uses only two simple blood tests [3]. Research shows that the ALBI grade is often more accurate than the Child-Pugh score at predicting how well a patient will survive treatment, especially with modern therapies like immunotherapy [4][5][6].
  • PALBI Grade: A variation of ALBI that also includes your platelet count, helping to better predict the risk of liver failure after procedures like surgery or TACE [7][8].

Beyond the Basics

While the BCLC system is the standard staging method, it has limitations—especially for intermediate and advanced stages where patients can be very different from one another [9]. Because of this, your team may use supplemental scoring tools or calculators behind the scenes. These models factor in specific details like your exact AFP levels or the strict measurements of your tumor to create a highly personalized treatment plan [10][11]. You do not need to memorize these systems, but it is reassuring to know your doctors are utilizing precise data to tailor your care.

The Most Powerful Predictors

In almost every risk model, certain “red flag” variables have the strongest impact on your long-term outlook:

  1. Microvascular Invasion (MVI): If cancer cells have entered the tiny blood vessels, the risk of recurrence is significantly higher [12][13].
  2. Tumor Burden: This is often measured using rules that calculate the sum of the tumor size and number. If you fall outside certain limits, standard treatments like TACE may be less effective [14][15].
  3. AFP (Alpha-fetoprotein): Higher levels (especially over 400 ng/mL) usually indicate a more aggressive tumor biology [16].
  4. Performance Status: Your ability to carry out daily tasks is a simple but powerful predictor of how well you will tolerate treatment [1].

Limitations of the Models

It is important to remember that these systems are based on averages from thousands of patients. They cannot perfectly predict an individual’s outcome. The heterogeneity (diversity) of HCC means that two patients with the “same” BCLC stage might have very different experiences [17]. This is why modern care increasingly uses a “multidisciplinary” approach to adjust these scores based on your unique health profile [2].

Common questions in this guide

How do doctors determine my hepatocellular carcinoma prognosis?
Your prognosis depends on two main factors: the aggressiveness of the tumor and the health of your remaining liver tissue. Doctors use scoring systems that measure liver function, combined with tumor size and blood markers, to estimate your overall outlook.
What is the ALBI grade for liver cancer?
The ALBI (Albumin-Bilirubin) grade is an assessment tool that uses two simple blood tests to measure your liver function. It is often more accurate than traditional methods at predicting how well you will tolerate treatments like immunotherapy.
What does microvascular invasion mean for my HCC prognosis?
Microvascular invasion means that cancer cells have entered the tiny blood vessels in your liver. When this is present, it indicates a more aggressive tumor biology and a higher risk of the cancer returning after treatment.
Why is my AFP level important for my liver cancer prognosis?
Alpha-fetoprotein (AFP) is a tumor marker that can be measured with a blood test. Higher AFP levels, especially over 400 ng/mL, typically suggest a more aggressive liver cancer and can influence which treatments will be most effective for you.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my albumin and bilirubin levels, what is my ALBI grade, and how does it affect my prognosis?
  2. 2.Do I have microvascular invasion (MVI) or satellite nodules? If so, how do these factors change my expected risk of the cancer returning?
  3. 3.Are you using any supplemental calculators to personalize my stage and treatment plan beyond the basic BCLC system?
  4. 4.How does my pre-treatment AFP level influence the long-term outlook for my specific type of HCC?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Risk factors of mortality in the patients with hepatocellular carcinoma: A multicenter study in Indonesia.

    Jasirwan COM, Hasan I, Sulaiman AS, et al.

    Current problems in cancer 2020; (44(1)):100480 doi:10.1016/j.currproblcancer.2019.05.003.

    PMID: 31130257
  2. 2

    Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

    Benson AB, D'Angelica MI, Abbott DE, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2021; (19(5)):541-565.

    PMID: 34030131
  3. 3

    Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma.

    Chan AW, Kumada T, Toyoda H, et al.

    Journal of gastroenterology and hepatology 2016; (31(7)):1300-6 doi:10.1111/jgh.13291.

    PMID: 26751608
  4. 4

    Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Carcinoma: A Large-Scale, Multi-Center Real-World Database Study.

    Kim KP, Kim KM, Ryoo BY, et al.

    Liver cancer 2024; (13(6)):610-628 doi:10.1159/000539724.

    PMID: 39687041
  5. 5

    Comparison of albumin-bilirubin grade versus Child-Pugh score in predicting the outcome of transarterial chemoembolization for hepatocellular carcinoma using time-dependent ROC.

    Zhao S, Zhang T, Li H, et al.

    Annals of translational medicine 2020; (8(8)):538 doi:10.21037/atm.2020.02.124.

    PMID: 32411761
  6. 6

    Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis.

    Tian BW, Yan LJ, Ding ZN, et al.

    International immunopharmacology 2023; (114()):109519 doi:10.1016/j.intimp.2022.109519.

    PMID: 36459922
  7. 7

    The platelet-albumin-bilirubin score in predicting hepatic failure after TACE for non-small hepatocellular carcinoma.

    Liang W, Yuan H, Zhou J, et al.

    Postgraduate medicine 2025; 1-8 doi:10.1080/00325481.2025.2587342.

    PMID: 41230948
  8. 8

    Comparison of platelet-albumin-bilirubin (PALBI), albumin-bilirubin (ALBI), and child-pugh (CP) score for predicting of survival in advanced hcc patients receiving radiotherapy (RT).

    Ho CHM, Chiang CL, Lee FAS, et al.

    Oncotarget 2018; (9(48)):28818-28829 doi:10.18632/oncotarget.25522.

    PMID: 29988960
  9. 9

    A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria.

    Wang YY, Zhong JH, Xu HF, et al.

    Alimentary pharmacology & therapeutics 2019; (49(2)):202-210 doi:10.1111/apt.15074.

    PMID: 30506713
  10. 10

    Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature.

    Campigotto M, Giuffrè M, Colombo A, et al.

    World journal of hepatology 2020; (12(12)):1239-1257 doi:10.4254/wjh.v12.i12.1239.

    PMID: 33442451
  11. 11

    Survival Predictability Between the American Joint Committee on Cancer 8th Edition Staging System and the Barcelona Clinic Liver Cancer Classification in Patients with Hepatocellular Carcinoma.

    Chen LJ, Chang YJ, Chang YJ

    The oncologist 2021; (26(3)):e445-e453 doi:10.1002/onco.13535.

    PMID: 32969134
  12. 12

    Systemic analysis identifying PVT1/DUSP13 axis for microvascular invasion in hepatocellular carcinoma.

    Su R, Zhang H, Zhang L, et al.

    Cancer medicine 2023; (12(7)):8937-8955 doi:10.1002/cam4.5546.

    PMID: 36524545
  13. 13

    Deep Learning With 3D Convolutional Neural Network for Noninvasive Prediction of Microvascular Invasion in Hepatocellular Carcinoma.

    Zhang Y, Lv X, Qiu J, et al.

    Journal of magnetic resonance imaging : JMRI 2021; (54(1)):134-143 doi:10.1002/jmri.27538.

    PMID: 33559293
  14. 14

    A new substage classification strategy for Barcelona Clinic Liver Cancer stage B patients with hepatocellular carcinoma.

    Hu KS, Tang B, Yuan J, et al.

    Journal of gastroenterology and hepatology 2019; (34(11)):1984-1991 doi:10.1111/jgh.14673.

    PMID: 30932246
  15. 15

    Advancing predictive oncology: Integrating clinical and radiomic models to optimize transarterial chemoembolization outcomes in hepatocellular carcinoma.

    Baddam S

    World journal of clinical cases 2025; (13(28)):109397 doi:10.12998/wjcc.v13.i28.109397.

    PMID: 40881015
  16. 16

    Predictors and long-term prognosis of early and late recurrence for patients undergoing hepatic resection of hepatocellular carcinoma: a large-scale multicenter study.

    Yan WT, Li C, Yao LQ, et al.

    Hepatobiliary surgery and nutrition 2023; (12(2)):155-168 doi:10.21037/hbsn-21-288.

    PMID: 37124678
  17. 17

    Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.

    Pecorelli A, Lenzi B, Gramenzi A, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2017; (37(3)):423-433 doi:10.1111/liv.13242.

    PMID: 27566596

This page explains prognostic models for hepatocellular carcinoma for educational purposes only. Your hepatologist and oncologist are the best sources for interpreting your specific risk scores and personal prognosis.

Get notified when new evidence is published on Adult hepatocellular carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.